Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity-Reference-Cited by-同舟云学术

Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity

Published:2018-11-09 Issue:2 Volume:368 Page:299-307
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Russell John P.,Mohammadi Ehsan,Ligon Casey O.^ORCID,Johnson Anthony C.,Gershon Michael D.,Rao Meenakshi,Shen Yuhong,Chan Chi-Chung,Eidam Hilary S.,DeMartino Michael P.,Cheung Mui,Oliff Allen I.,Kumar Sanjay,Greenwood-Van Meerveld Beverley

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference34 articles.

1. The GDNF family: Signalling, biological functions and therapeutic value

2. Mechanisms of hypersensitivity in IBS and functional disorders

3. The GDNF family ligands and receptors — implications for neural development

4. RET inhibition: implications in cancer therapy;Borrello;Expert Opin Ther Targets,2013

5. Neuroplasticity and dysfunction after gastrointestinal inflammation

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RET Signaling Persists in the Adult Intestine and Stimulates Motility by Limiting PYY Release From Enteroendocrine Cells;Gastroenterology;2023-11

2. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present);Expert Opinion on Therapeutic Patents;2022-10-03

3. Effects of Commercial Probiotics on Colonic Sensitivity after Acute Mucosal Irritation;International Journal of Environmental Research and Public Health;2022-05-26

4. RET Signaling Persists in the Adult Intestine and Stimulates Motility by Limiting PYY Release from Enteroendocrine Cells;2022-04-16

5. Emerging therapies in the management of Irritable Bowel Syndrome (IBS);Expert Opinion on Emerging Drugs;2022-01-02